LATE BREAKING ABSTRACT: CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell...

Date 26 September 2015
Event European Cancer Congress 2015
Session Presidential Session I
Topics Renal Cell Cancer
Presenter Sharma, P.